Michael Okunewitch
Stock Analyst at Maxim Group
(0.60)
# 4,139
Out of 5,172 analysts
26
Total ratings
24%
Success rate
-14.84%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.19 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.13 | +784.96% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $0.64 | +832.98% | 3 | Sep 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $0.74 | +4,639.34% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $4.80 | +150.26% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.78 | +1,473.03% | 2 | Feb 20, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.45 | +106.90% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $2.04 | +96.08% | 1 | Oct 15, 2024 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.25 | +4,624.41% | 1 | Sep 24, 2024 | |
| LGVN Longeveron | Maintains: Buy | $15 → $6 | $0.98 | +512.24% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.71 | +1,582.32% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.66 | +1,345.78% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.09 | +761.24% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $1.83 | +110,555.74% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $16.96 | +47.41% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.28 | +2,043.62% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.49 | +616.33% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.77 | +12,876.90% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.19
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.13
Upside: +784.96%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $0.64
Upside: +832.98%
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $0.74
Upside: +4,639.34%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $4.80
Upside: +150.26%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.78
Upside: +1,473.03%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.45
Upside: +106.90%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $2.04
Upside: +96.08%
FibroBiologics
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.25
Upside: +4,624.41%
Longeveron
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.98
Upside: +512.24%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.71
Upside: +1,582.32%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $1.66
Upside: +1,345.78%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.09
Upside: +761.24%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $1.83
Upside: +110,555.74%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $16.96
Upside: +47.41%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $0.28
Upside: +2,043.62%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.49
Upside: +616.33%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.77
Upside: +12,876.90%